These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient. Hoashi T; Hirabayashi M; Nakajima R; Takahashi N; Saeki H J Dermatol; 2017 Sep; 44(9):1078-1079. PubMed ID: 27726177 [No Abstract] [Full Text] [Related]
4. A rare case: Hallucination associated with pazopanib. Demirci NS; Erdem GU; Dogan M; Ozdemir NY; Zengin N J Cancer Res Ther; 2015; 11(4):961-2. PubMed ID: 26881556 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome. Hayashi M; Makino T; Mori N; Mizawa M; Shimizu T Eur J Dermatol; 2020 Feb; 30(1):68-69. PubMed ID: 32250262 [No Abstract] [Full Text] [Related]
12. Pazopanib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: A Case Report. Singh P; DʼAngelo RN; Huang V Am J Ther; 2019; 26(5):e636-e638. PubMed ID: 30946042 [No Abstract] [Full Text] [Related]
13. Pazopanib outscores sunitinib on tolerability. Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960 [TBL] [Abstract][Full Text] [Related]
14. Angiosarcoma of the scalp successfully treated with pazopanib. Tomita H; Koike Y; Asai M; Ogawa F; Abe K; Tanioka M; Utani A J Am Acad Dermatol; 2014 Jan; 70(1):e19-21. PubMed ID: 24176520 [No Abstract] [Full Text] [Related]
15. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma. Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601 [No Abstract] [Full Text] [Related]
16. Periosteal Reaction Possibly Induced by Pazopanib: A Case Report and Literature Review. Hosokawa T; Hara T; Arakawa Y; Oguma E; Yamada Y J Pediatr Hematol Oncol; 2020 Nov; 42(8):e822-e825. PubMed ID: 31567787 [TBL] [Abstract][Full Text] [Related]
17. An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: A case of myxofibrosarcoma. Uwa N; Terada T; Mohri T; Tsukamoto Y; Futani H; Demizu Y; Okimoto T; Sakagami M Auris Nasus Larynx; 2017 Aug; 44(4):484-488. PubMed ID: 27523716 [TBL] [Abstract][Full Text] [Related]
18. Tumour-bowel fistula as a possible complication of pazopanib therapy in retroperitoneal leiomyosarcoma. Pereira ROL; Patel PR; Guru PK; Sanghavi DK BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31712231 [TBL] [Abstract][Full Text] [Related]
19. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma. Miura H; Shirai H Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734 [No Abstract] [Full Text] [Related]
20. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma. Kitamura S; Hata H; Imafuku K; Haga N; Homma E; Shimizu H Clin Exp Dermatol; 2015 Dec; 40(8):931-3. PubMed ID: 25817046 [No Abstract] [Full Text] [Related] [Next] [New Search]